Pharmaceutical Research

, Volume 30, Issue 1, pp 1–15

A Physiologically Based Pharmacokinetic Model of the Minipig: Data Compilation and Model Implementation

Expert Review

DOI: 10.1007/s11095-012-0911-5

Cite this article as:
Suenderhauf, C. & Parrott, N. Pharm Res (2013) 30: 1. doi:10.1007/s11095-012-0911-5


In today’s pharmaceutical research and development, physiologically-based pharmacokinetic (PBPK) modeling plays an important role in the design, evaluation and interpretation of pharmacokinetic, toxicokinetic and formulation studies. PBPK models incorporate in vitro physicochemical and biochemical data in a physiologically based model framework to simulate in vivo exposure. The comparison of simulated concentrations to those measured in in vivo studies can be used to gain insights into compound behavior and to inform PBPK based human pharmacokinetic predictions. The Göttingen minipig is gaining importance as a large animal model in pharmaceutical research due to its physiological and anatomical similarities to human and is increasingly replacing dog and non-human primate in preclinical studies. However, no PBPK model for minipig has yet been published. This review discusses the information available to establish the physiological database for this species and highlights the gaps in current knowledge. A preliminary PBPK model is created from this database and simulations for two drugs dosed both intravenously and orally are compared to measured plasma concentrations. Results support the validity of the model with simulated plasma concentrations within the range of the observations. In conclusion, the model will need to be refined as additional physiological data become available, but it can already provide useful simulations to assist pharmaceutical research and development in the minipig.


absorption modeling distribution elimination intestinal absorption metabolism minipig physiologically based pharmacokinetic modeling pig 



Advanced Compartmental Absorption and Transit


Biopharmaceutics Classification System


cardiac output


cytochrome P450


fraction of dose absorbed


glomerular filtration rate




physiologically based pharmacokinetic




surface area enhancement factor

Supplementary material

11095_2012_911_MOESM1_ESM.doc (110 kb)
ESM 1(DOC 109 kb)

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.F. Hoffmann-La Roche Ltd., Pharmaceuticals DivisionNon-Clinical SafetyBaselSwitzerland
  2. 2.F. Hoffmann-La Roche Ltd., Pharmaceuticals DivisionNon-Clinical SafetyBaselSwitzerland

Personalised recommendations